GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » Price-to-Tangible-Book

NexImmune (NexImmune) Price-to-Tangible-Book : 1.11 (As of May. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NexImmune Price-to-Tangible-Book?

As of today (2024-05-07), NexImmune's share price is $3.65. NexImmune's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.29. Hence, NexImmune's Price to Tangible Book Ratio of today is 1.11.

The historical rank and industry rank for NexImmune's Price-to-Tangible-Book or its related term are showing as below:

NEXI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.2   Med: 0.67   Max: 1.26
Current: 1.11

During the past 6 years, NexImmune's highest Price to Tangible Book Ratio was 1.26. The lowest was 0.20. And the median was 0.67.

NEXI's Price-to-Tangible-Book is ranked better than
81.83% of 1222 companies
in the Biotechnology industry
Industry Median: 2.73 vs NEXI: 1.11

A closely related ratio is called PB Ratio. As of today, NexImmune's share price is $3.65. NexImmune's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.29. Hence, NexImmune's P/B Ratio of today is 1.11.


NexImmune Price-to-Tangible-Book Historical Data

The historical data trend for NexImmune's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Price-to-Tangible-Book Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial - - 1.26 0.20 0.67

NexImmune Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.42 0.43 0.67 0.67

Competitive Comparison of NexImmune's Price-to-Tangible-Book

For the Biotechnology subindustry, NexImmune's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexImmune's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NexImmune's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where NexImmune's Price-to-Tangible-Book falls into.



NexImmune Price-to-Tangible-Book Calculation

NexImmune's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=3.65/3.292
=1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


NexImmune Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of NexImmune's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


NexImmune (NexImmune) Business Description

Traded in Other Exchanges
N/A
Address
9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Executives
Alan S. Roemer director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover officer: VP, Corporate Controller C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao director 10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi director C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke officer: Chief Science Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones officer: Chief Operating Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis officer: EVP of R&D 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer director, officer: President and CEO C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer officer: Chief Financial Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight officer: Chief Medical Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877